Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Cash Flow (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Net Cash Flow data on record, last reported at -$8.5 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 280.31% year-over-year to -$8.5 million; the TTM value through Dec 2025 reached $27.0 million, up 208.37%, while the annual FY2025 figure was $27.0 million, 208.37% up from the prior year.
  • Net Cash Flow reached -$8.5 million in Q4 2025 per FHTX's latest filing, down from $16.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $112.5 million in Q1 2022 and bottomed at -$152.4 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$520100.0, with a median of $6.3 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 745.28% in 2024, down 744.84% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $43.3 million in 2021, then plummeted by 181.8% to -$35.4 million in 2022, then soared by 128.32% to $10.0 million in 2023, then crashed by 122.17% to -$2.2 million in 2024, then crashed by 280.31% to -$8.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$8.5 million in Q4 2025, $16.8 million in Q3 2025, and $13.1 million in Q2 2025.